GLP-1受体激动剂对卒中、蛛网膜下腔出血和脑出血的影响:倾向匹配多机构队列研究
该回顾性队列研究利用TriNetX数据(2014-2024)分析GLP-1受体激动剂对动脉瘤性蛛网膜下腔出血、自发性脑出血和急性缺血性卒中患者结局及发病率的影响。倾向匹配后显示,GLP-1受体激动剂使用与各卒中亚型死亡率降低、并发症减少及卒中总体发病率下降相关,不良事件相似。
要点
- aSAH患者使用GLP-1-RAs与6个月再出血和死亡率降低相关。
- sICH患者使用GLP-1-RAs与6个月和1年脑积水、癫痫及死亡率降低相关。
- AIS患者使用GLP-1-RAs与6个月和1年死亡率及复发率降低相关。
核心结论
- GLP-1-RAs与各卒中亚型生存改善和并发症减少相关,并降低出血性和缺血性卒中发病率。
研究设计与样本
- 回顾性研究利用TriNetX数据(2014-2024)识别aSAH、sICH或AIS患者。
- 诊断后8周内使用exenatide、lixisenatide、semaglutide、dulaglutide、liraglutide或tirzepatide者与对照进行倾向匹配。
主要发现
- aSAH患者6个月再出血OR 0.73(p=0.003)、死亡率OR 0.41(p<0.001);1年认知缺陷OR 0.63(p=0.034)、死亡率OR 0.39(p<0.001)。
- sICH患者6个月脑积水OR 0.37(p=0.005)、癫痫OR 0.56(p=0.007);1年脑积水OR 0.38(p=0.007)、癫痫OR 0.63(p=0.018),死亡率OR 0.45-0.40(均p<0.001),再出血OR 0.70-0.69(均p<0.001)。
- AIS患者6个月死亡率OR 0.27(p<0.001)、1年OR 0.44(p<0.001),6个月复发OR 0.60(p<0.001)、脑积水OR 0.32(p<0.001)、癫痫OR 0.43(p<0.001)。
- 1年时GLP-1-RA使用者SAH发病率OR 0.64(p=0.001)、ICH OR 0.62(p<0.001)、AIS OR 0.82(p=0.003),2年持续(ORs 0.77-0.87,均p<0.05)。
- 不良事件相似。
临床怎么用
- 对于aSAH、sICH和AIS患者,使用GLP-1-RAs可能与改善生存和减少并发症相关。
- 需前瞻性试验确认这些观察结果。
局限性
- 为回顾性研究设计。
- 需前瞻性试验确认观察结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The authors evaluated whether glucagon-like peptide-1 receptor agonists (GLP-1-RAs) improve outcomes in patients with aneurysmal subarachnoid hemorrhage (aSAH), spontaneous intracerebral hemorrhage (sICH), and acute ischemic stroke (AIS) and reduce the overall incidence of these events. METHODS: This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS. Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls. Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years. RESULTS: For aSAH patients, GLP-1-RA use at 6 months reduced rebleeding (OR 0.73, p = 0.003) and mortality (OR 0.41, p < 0.001) and at 1 year lowered cognitive deficits (OR 0.63, p = 0.034) and mortality (OR 0.39, p < 0.001). In sICH patients, GLP-1-RAs decreased hydrocephalus (OR 0.37, p = 0.005) and seizures (OR 0.56, p = 0.007) at 6 months, with persistent benefits at 1 year (hydrocephalus, OR 0.38, p = 0.007; seizures, OR 0.63, p = 0.018), alongside lower mortality (OR 0.45-0.40, both p < 0.001) and rebleeding (OR 0.70-0.69, both p < 0.001) rates. In AIS patients, mortality fell at 6 months (OR 0.27, p < 0.001) and 1 year (OR 0.44, p < 0.001), with reduced recurrence (OR 0.60, p < 0.001) and lower hydrocephalus (OR 0.32, p < 0.001) and seizure (OR 0.43, p < 0.001) rates at 6 months. At 1 year, GLP-1-RA users had lower incidence rates of SAH (OR 0.64, p = 0.001), ICH (OR 0.62, p < 0.001), and AIS (OR 0.82, p = 0.003), which were sustained at 2 years (ORs 0.77-0.87, all p < 0.05). Adverse events were similar. CONCLUSIONS: GLP-1-RAs were associated with improved survival and fewer complications across stroke subtypes, plus reduced hemorrhagic and ischemic stroke incidence. Prospective trials are warranted to confirm these observations.
引用
- Costa M, O'Leary S, Price AM, et al. Impact of GLP-1 receptor agonists on stroke, subarachnoid hemorrhage, and intracerebral hemorrhage: a propensity-matched multi-institutional cohort study. J Neurosurg. 2025. PMID: 41043189. doi:10.3171/2025.5.JNS25786
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。